New drug cocktail aims to boost remission in rare blood cancer

NCT ID NCT04263480

Ongoing Disease control Sponsor: Christian Buske Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether adding carfilzomib to ibrutinib improves outcomes for people with Waldenström's macroglobulinemia, a rare blood cancer. About 99 participants will receive either the combination or ibrutinib alone. The goal is to see if the combo leads to higher rates of very good partial or complete remission after 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Carfilzomib and Ibrutinib
What this could lead to: If successful, this combination could offer a more effective chemotherapy-free option for Waldenström's macroglobulinemia, especially for patients with certain genetic profiles.
What could go wrong: This is a Phase 2 trial with 99 participants, so results are preliminary. The combination may not prove significantly better than ibrutinib alone, and side effects from adding carfilzomib could be higher.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

WALDENSTROM MACROGLOBULINEMIA

Contacts and locations

Locations

Alexandra Hospital

Athens, 11528, Greece
Bruederkrankenhaus St. Josef

Paderborn, 33098, Germany
Ev. Diakoniekrankenhaus

Bremen, 28239, Germany
Gemeinschaftspraxis Mohm / Prange-Krex

Dresden, 01307, Germany
Hämatologie/Onkologie München Pasing MVZ GmbH

Munich, 81241, Germany
Hämatologisch-Onkologische Schwerpunktpraxis Drs. Schöttker & Pretscher

Würzburg, 97080, Germany
Kath. St.-Johannes-Gesellschaft Dortmund gGmbH

Dortmund, 44137, Germany
Kliniken Ostalb, Staufenklinikum Schw. Gmuend

Mutlangen, 72557, Germany
MediProject Onkologisches Ambulanzzentrum Hannover

Hanover, 30171, Germany
Medizinische Universität Wien

Vienna, 1090, Austria
OncoResearch Lerchenfeld GmbH

Hamburg, 22081, Germany
Praxis Dr. Vehling-Kaiser

Landshut, 84130, Germany
Praxis für Hämatologie und Onkologie, onkologische Tagesklinik-VK&K Studien GbR

Landshut, 84036, Germany
Uniklinikum Salzburg

Salzburg, 5020, Austria
University Hospital Ulm

Ulm, 89081, Germany
Universitätsmedizin Rostock

Rostock, 18055, Germany
Vivantes Klinikum am Urban

Berlin, 10967, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.